Literature DB >> 10219803

Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers.

C Marchal1, B Weber, B de Lafontan, M Resbeut, H Mignotte, P P du Chatelard, B Cutuli, M Reme-Saumon, A Broussier-Leroux, G Chaplain, F Lesaunier, J M Dilhuydy, J L Lagrange.   

Abstract

OBJECTIVES: To conduct a survey of the angiosarcomas developing after breast conservation for carcinoma in the French Cancer Centers, to study the evolution of these cases in detail, and to review literature in an attempt to propose an optimal treatment scheme.
MATERIAL AND METHODS: Eleven of the 20 French Cancer Centers agreed to research and retrospectively analyze all angiosarcomas discovered in patients previously treated by conservative treatment. The majority of the patients were node negative, T1N0M0. The mean age of the patients at the time of primary breast cancer treatment was 62.5 years, and 69 years at the diagnosis of the angiosarcoma.
RESULTS: During the last two decades, nearly 20,000 patients have been treated conservatively in these 11 centers, and only 9 cases of angiosarcoma were found. The median latency period between the treatment of the breast carcinoma and the diagnosis of the breast angiosarcoma was approximately 74 months, with a range of 57-108 months. Mastectomy was performed as the main treatment of this angiosarcoma. All recurrences after mastectomy for the angiosarcoma appeared within 16 months after the mastectomy. A median time of recurrence was found to be 7.5 months, regardless of the treatment. The angiosarcomas appeared to be very aggressive, and chemotherapy, radiotherapy, and sometimes hyperthermia could only palliate the condition for a short time. After the diagnosis of angiosarcoma, the median survival was 15.5 months, showing a particularly poor prognosis. Only 1 patient of 9 is alive without progressive disease at 32 months after salvage mastectomy for the recurrence of the angiosarcoma. Precise data obtained from 11 centers show that, of 18115 breast carcinomas treated conservatively, only 9 breast angiosarcomas are reported, which represents a prevalence of 5 cases of angiosarcoma per 10,000, which is the same prevalence for primary breast angiosarcomas occurring in healthy breasts.
CONCLUSION: Angiosarcoma developing after breast conserving therapy for carcinoma is a rare event, and induction of it by treatment is controversial. However, early diagnosis is essential and it appears that radical mastectomy gives the highest chance of cure and the best long-term survival.

Entities:  

Mesh:

Year:  1999        PMID: 10219803     DOI: 10.1016/s0360-3016(98)00537-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  27 in total

1.  Secondary cancers after radiotherapy may appear early and atypical.

Authors:  T Baack; F Wenz
Journal:  Strahlenther Onkol       Date:  2011-12-23       Impact factor: 3.621

2.  Angiosarcoma of the breast. Two cases following breast conserving treatment for invasive carcinoma.

Authors:  A Fernández Ortega; J M Gil Gil; A Urruticoetxea; J M Serra Payró
Journal:  Clin Transl Oncol       Date:  2006-07       Impact factor: 3.405

3.  Large clinical experience of primary angiosarcoma of the breast in a single Korean medical institute.

Authors:  Soo Youn Bae; Min-Young Choi; Dong Hui Cho; Jeong Eon Lee; Seok Jin Nam; Jung-Hyun Yang
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

4.  Clinicopathologic features of Stewart-Treves syndrome.

Authors:  Ling-Ling Wang; Li-Fang Cui; Ying Gao; Zhong-Cai Jiang
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

5.  Effect of a combined surgery, re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall.

Authors:  M Linthorst; A N van Geel; E A Baartman; S B Oei; W Ghidey; G C van Rhoon; J van der Zee
Journal:  Strahlenther Onkol       Date:  2013-04-04       Impact factor: 3.621

Review 6.  [Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review].

Authors:  Carolin Nestle-Krämling; Edwin Bölke; Wilfried Budach; Matthias Peiper; Dieter Niederacher; Wolfgang Janni; Claus Ferdinand Eisenberger; Wolfram Trudo Knoefel; Axel Scherer; Stephan Ernst Baldus; Guido Lammering; Peter Arne Gerber; Christiane Matuschek
Journal:  Strahlenther Onkol       Date:  2011-08-16       Impact factor: 3.621

7.  Four cases of echogenic breast lesions: a case series and review.

Authors:  Lin Wah Goh; Su Lin Jill Wong; Puay Hoon Tan
Journal:  Singapore Med J       Date:  2016-02-19       Impact factor: 1.858

8.  Clinical management of secondary angiosarcoma after breast conservation therapy.

Authors:  Martina Zemanova; Katarina Machalekova; Monika Sandorova; Elena Boljesikova; Marta Skultetyova; Juraj Svec; Andrej Zeman
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-23

9.  Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience.

Authors:  Darya Buehler; Stephanie R Rice; John S Moody; Patrick Rush; Gholam-Reza Hafez; Steven Attia; B Jack Longley; Kevin R Kozak
Journal:  Am J Clin Oncol       Date:  2014-10       Impact factor: 2.339

10.  A breast surgeon's paranoia pays off: the importance of keen clinical acumen in a case of postradiotherapy breast angiosarcoma.

Authors:  Adeel Zafar; Peter Neary; Gerrard O'Donoghue; Constantino Fiuza-Castinieria
Journal:  BMJ Case Rep       Date:  2012-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.